MedTrace Logo

Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State

NCT02223065 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2016-04-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate bioequivalence of coadministered drugs on healthy subjects.

Conditions

Interventions

DRUG

Saxagliptin

DRUG

Dapagliflozin

Sponsors & Collaborators

Principal Investigators

  • Michael Gartner, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02223065 on ClinicalTrials.gov